Search results for "Compound"

showing 10 items of 35174 documents

One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

2021

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BControl (management)Guidelinechemistry.chemical_compoundRisk FactorsCardiovascular DiseasePrimary preventionCardiovascular disease DyslipidemiaInternal MedicineHumansMedicineIntensive care medicineDyslipidemiasSecondary preventionPrimary preventionbiologybusiness.industryCholesterolSecondary preventionLDL-C treatmentCholesterol LDLGuidelineAtherosclerosisClinical trialCholesterolchemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Risk Factors: AtherosclerosiHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessEuropean Journal of Internal Medicine
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

Impact of chronic diuretic treatment on glucose homeostasis

2013

Background The use of diuretics for hypertension has been associated with unfavorable changes in cardiovascular risk factors, such as uric acid and glucose tolerance, though the findings in the literature are contradictory. Methods This study investigated whether diuretic use is associated with markers of metabolic and cardiovascular risk, such as insulin-resistance and uric acid, in a cohort of adults without known diabetes and/or atherosclerotic cardiovascular disease. Nine hundred sixty-nine randomly selected participants answered a questionnaire on clinical history and dietary habits. Laboratory blood measurements were obtained in 507 participants. Results Previously undiagnosed type 2 …

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateType 2 diabetesGastroenterologySettore MED/13 - Endocrinologiachemistry.chemical_compoundInsulin resistanceDiabetes mellitusInternal medicineInternal MedicinemedicineGlucose homeostasisSettore MED/49 - Scienze Tecniche Dietetiche ApplicateDiureticsbusiness.industryResearchInsulin resistanceType 2 diabetesmedicine.diseaseDiuretics Hypertension Insulin resistance Type 2 diabetes Uric acidEndocrinologychemistryHypertensionCohortUric acidDiureticbusinessUric acidBody mass index
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Halitosis: new insight into a millennial old problem.

2011

The problem of halitosis has been reported since ancienttimes. References have been found in papyrus manuscriptsdating back to 1550 BC. Hippocrates advised that any girlshould have pleasant breath, making sure always to washher mouth with wine, anise and dill seeds [1].More than50 years ago, Blackburn [2] investigated halitosis in a case-series of 73 patients affected by leukemia. He found apeculiar odor of the breath resembling that of a freshlyopened corpse. This characteristic smell is not associatedwith clinical involvement of the gum, mouth, or upperrespiratory or alimentary tract. He associated this particularsmell with the hematologic disease. Nearly 15 years ago,the role of cadaveri…

medicine.medical_specialtySettore MED/09 - Medicina InternaPopulationDentistryOral HealthOral hygienechemistry.chemical_compoundBad breathInternal MedicinemedicineHumansPutrefactioneducationeducation.field_of_studyCadaverinebusiness.industryHalitosisOral HygieneDermatologySettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatrichechemistryOdorEmergency MedicineEtiologyPutrescinemedicine.symptombusinessMouth DiseasesInternal and emergency medicine
researchProduct

Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observationa…

2018

The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clar…

medicine.medical_specialtySettore MED/09 - Medicina InternaPrognosiEpidemiologyPopulationDiseaseHyperuricemia030204 cardiovascular system & hematologyRisk AssessmentCardiovascular disease; Epidemiology; Uric acid; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid; Internal Medicine; Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetrospective StudieRisk FactorsInternal medicineEpidemiologymedicineInternal MedicineHumansHyperuricemiaRisk factoreducationRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseCardiovascular diseasePrognosisUric AcidchemistryItalyCardiovascular DiseasesResearch DesignUric acidCardiovascular disease; Epidemiology; Uric acidbusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersHumanHigh blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension
researchProduct

Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria

2017

The kidney is one of the major target organs of hypertension. Kidney damage represents a frequent event in the course of hypertension and arterial hypertension is one of the leading causes of end-stage renal disease (ESRD). ESRD has long been recognized as a strong predictor of cardiovascular (CV) morbidity and mortality. However, over the past 20 years a large and consistent body of evidence has been produced suggesting that CV risk progressively increases as the estimated glomerular filtration rate (eGFR) declines and is already significantly elevated even in the earliest stages of renal damage. Data was supported by the very large collaborative metaanalysis of the Chronic Kidney Disease …

medicine.medical_specialtySettore MED/09 - Medicina InternaRenal function030204 cardiovascular system & hematologyAsymptomatic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030212 general & internal medicineSubclinical infectionSettore MED/14 - NefrologiaKidneyCreatinineProteinuriabusiness.industryArterial hypertension • Blood pressure • Glomerular filtration rate • Microalbuminuria • Proteinuria • Subclinical renal disease • Early kidney injury • Target organ damage • Cardiovascular disease • Cardiovascular risk assessmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureEndocrinologychemistryCardiologyMicroalbuminuriamedicine.symptombusinessKidney disease
researchProduct

BENEFICIAL EFFECT OF PROBIOTICS ADMINISTRATION IN INFLAMMATORY BOWEL DISEASE AND RELATED SPONDYLOARTHROPATHY: A PROSPECTIVE STUDY

2015

Background: Therapeutic treatment for inflammatory bowel disease (IBD) may follow different approaches, systemic as well as local, especially when the target is the osteoarticular apparatus. Although some clinical trials have suggested benefits from probiotics administration in IBD, there is still a great deal of controversy on their use. The aim of this study was to further investigate the effects of probiotics in patients with IBD and related spondyloarthropathy. Material/Methods: Fifty-nine patients affected by IBD with extra-intestinal involvement where evaluated from 2006 to 2010. Twenty-eight patients received administration of a standard therapy with mesalazine and 31 where treated w…

medicine.medical_specialtySettore MED/09 - Medicina InternaSpondyloarthropathyBiomedical EngineeringBioengineeringInflammatory bowel diseaseGastroenterologylaw.inventionchemistry.chemical_compoundProbioticMesalazineRandomized controlled triallawInternal medicinemedicineIn patientProspective cohort studyGeneral PsychologyInflammatory Bowel Disease IBD Microbiome Dysbiosis MALTbusiness.industrySettore BIO/16 - Anatomia UmanaGeneral Medicinemedicine.diseaseClinical trialSettore MED/18 - Chirurgia Generalechemistrybusiness
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct